Cargando…
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
BACKGROUND: Development of new therapies for Alzheimer's disease (AD) is increasingly focused on more mildly affected populations, and requires new assessment and outcome strategies. Patients in early stages of AD have mild cognitive decline and no, or limited, functional impairment. To respond...
Autores principales: | Wang, Jinping, Logovinsky, Veronika, Hendrix, Suzanne B, Stanworth, Stephanie H, Perdomo, Carlos, Xu, Lu, Dhadda, Shobha, Do, Ira, Rabe, Martin, Luthman, Johan, Cummings, Jeffrey, Satlin, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013117/ https://www.ncbi.nlm.nih.gov/pubmed/27010616 http://dx.doi.org/10.1136/jnnp-2015-312383 |
Ejemplares similares
-
Prognostic biomarkers in prodromal α-synucleinopathies: DAT binding and REM sleep without atonia
por: Kunz, Dieter, et al.
Publicado: (2023) -
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016) -
GSN gene frameshift mutations in Alzheimer’s disease
por: Jiang, Yaling, et al.
Publicado: (2023) -
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease
por: Singleton, Ellen, et al.
Publicado: (2021) -
CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
por: Teuber-Hanselmann, Sarah, et al.
Publicado: (2020)